biostudies-literatureUnknown19(2)Leal LIn 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission Clinical and translational sciencee70491https://www.ebi.ac.uk/biostudies/studies/S-EPMC12874496biostudies-literatureEffects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial.PMC12874496Carbonell IVergara AParedes RCastro PLaguno MSegui FMarco-Hernandez JPich JChumbita MPuerta-Alcalde PPadrosa JCastan CFerrer EGonzalez-Cordon ARico VSILCOR study groupFernandez SSoriano ACalvo JMuelas MMarcos MARojas JCamprubi DLopez-Soto ASola MDalmau DAlmuedo AGarcia FVentosa HFeliu MTuset Mde Alba MTBodro MCapdevila AGabara CCarbonell CGarcia-Vidal CRibot JNaval JTellez ARodriguez NMatas AAldea APinazo MJLadino Ade Lazzari EDel Puerto Bernoy Gonzalez MMartinez JAAguero DMoreno AMeira FDel Rio AGarcia-Pouton NMunoz JAmbrosioni JRubio EHernandez-Meneses MPellice MMarti HLeal LUgarte ATorres BFernandez MHerrera SAlvarez MFoncillas AMorata LRodriguez-Nunez OCardozo CDuenas GInciarte AZamora-Martinez CTome APrieto-Gonzalez Sde la Mora LGrau BGrafia IMoreno PfalseEffects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical Trial.In 2020, COVID-19 caused a global health crisis, prompting research efforts and accelerating drug development. As part of this response, we conducted a phase 2b, multicentre, open-label, randomized (1:1) clinical trial to compare the effects of siltuximab versus corticosteroids on disease progression in hospitalized adults with COVID-19 pneumonia. Between April 2020 and January 2021, 82 patients were randomized to receive siltuximab and 80 corticosteroids (20 methylprednisolone and 60 dexamethasone). Median (IQR) age was 61 years (50-72). Nineteen patients allocated to siltuximab were admitted to the intensive care unit compared to eight receiving corticosteroids (p = 0.025). Corticosteroid treatment was independently associated with a higher risk of avoiding intensive care unit admission 2026-01-01T00:00:00Z2026 Feb2026-07-15T09:07:12.961Z2026-07-02T03:08:46.557ZS-EPMC128744964164184810.1111/cts.70491